Search results for: Multi-Indication Medicines
Filter search results
HTAinSite: Recent Changes in the Database of NICE Decisions
7 June 2012
…about HTAinSite, in May 2010, the service has evolved in important ways. Added, for example, is the option of including the decisions of the Scottish Medicines Consortium (SMC) in the…
Spotlight on OHE: Development and Use of Measures of Health Worldwide
16 July 2012
…that when implemented in the UK in 2014, VBP will broaden the definition of value of medicines beyond health effects. The use of evidence in decision making was the subject…
OHE has an Opening for an Economist
4 September 2012
…sector; familiarity with HTA and medicines pricing and reimbursement in practice in one or more countries; strong quantitative skills Applications must be received by Monday, 24 September 2012. Interviews for…
New Research by OHE and University of Glasgow on cost of QALYs in Scotland
17 December 2012
…importance, especially given the Government’s desire to move towards “value based” pricing of new medicines in the future. The threshold may be thought of as the incremental cost per QALY…
Review of Plans for Refining Patient-Reported Outcomes Measures
19 February 2013
…medicines. The EQ-5D is the principal instrument for measuring health related quality of life for HTA purposes, making planned developments in EQ-5D instruments and value sets important in decision making….
OHE Welcomes Professors Rawlins and Smith to its Policy Board
6 May 2013
…2013. A physician and pharmacologist, Sir Michael has provided insight in numerous roles, including as head of both the Committee on Safety of Medicines and the Advisory Council on the…
Exploring the Link Between Health and Wealth in Government Decision Making
16 May 2013
…does decision making take into account that the investment in health care, including medicines interventions, can improve economic output. Barriers to a broader perspective included system fragmentation that precludes taking…
What Is the Role of Cost-Effectiveness Evidence in US Health Care?
31 July 2013
…Chambers discussed to what extent coverage decisions for medicines are consistent with cost-effectiveness evidence and what might be gained by explicitly including economic evidence in Medicare coverage policy — in…
ISPOR Task Force Report on Performance-Based Risk-Sharing Arrangements
28 August 2013
…Severens, Erasmus University Rotterdam; Paolo Siviero, AIFA (Italian Medicines Agency); and Miguel Sleeper, GlaxoSmithKline. For a recent slide presentation by Prof Towse that discusses PBSRAs, please click here. …